Integrative medicine considerations for convalescence from mild-to-moderate COVID-19 disease

被引:15
|
作者
Alschuler, Lise [1 ,2 ]
Chiasson, Ann Marie [1 ,2 ]
Horwitz, Randy [1 ,2 ]
Sternberg, Esther [1 ,2 ]
Crocker, Robert [1 ,2 ]
Weil, Andrew [2 ,3 ]
Maizes, Victoria [1 ,2 ]
机构
[1] Univ Arizona, Coll Med, Tucson, AZ 85721 USA
[2] Andrew Weil Ctr Integrat Med, Tucson, AZ 85711 USA
[3] Univ Arizona, Tucson, AZ 85721 USA
关键词
Integrative medicine; COVID-19; Immune; Diet; Supplements; Osteopathic manipulation; Qigong; Exercise; Stress reduction; Creative expression; Aromatherapy; RANDOMIZED CONTROLLED-TRIAL; QUALITY-OF-LIFE; FUNCTIONAL RECEPTOR; PHYSICAL HEALTH; IMMUNE FUNCTION; LUNG-FUNCTION; DOUBLE-BLIND; EXERCISE; QIGONG; SLEEP;
D O I
10.1016/j.explore.2020.12.005
中图分类号
R [医药、卫生];
学科分类号
10 ;
摘要
The majority of individuals infected with SARS-CoV-2 have mild-to-moderate COVID-19 disease. Convalescence from mild-to-moderate (MtoM) COVID-19 disease may be supported by integrative medicine strategies. Integrative Medicine (IM) is defined as healing-oriented medicine that takes account of the whole person, including all aspects of lifestyle. Integrative medicine strategies that may support recovery from MtoM COVID-19 are proposed given their clinically studied effects in related conditions. Adoption of an antiinflammatory diet, supplementation with vitamin D, glutathione, melatonin, Cordyceps, Astragalus and garlic have potential utility. Osteopathic manipulation, Qigong, breathing exercises and aerobic exercise may support pulmonary recovery. Stress reduction, environmental optimization, creative expression and aromatherapy can provide healing support and minimize enduring trauma. These modalities would benefit from clinical trials in people recovering from COVID-19 infection. (c) 2020 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
引用
收藏
页码:140 / 148
页数:9
相关论文
共 50 条
  • [21] Mild or Moderate Covid-19
    Gandhi, Rajesh T.
    Lynch, John B.
    del Rio, Carlos
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (18): : 1757 - 1766
  • [22] Regional moderate hyperthermia for mild-to-moderate COVID-19 (TherMoCoV study): a randomized controlled trial
    Mancilla-Galindo, Javier
    Kammar-Garcia, Ashuin
    Mendoza-Gertrudis, Maria de Lourdes
    Garcia Acosta, Javier Michael
    Nava Serrano, Yanira Saralee
    Santiago, Oscar
    Torres Vasquez, Miriam Berenice
    Martinez Martinez, Daniela
    Fernandez-Urrutia, Liliana Aline
    Robledo Pascual, Julio Cesar
    Narvaez Morales, Ivan Daniel
    Velasco-Medina, Andrea Aida
    Mancilla-Ramirez, Javier
    Figueroa-Damian, Ricardo
    Galindo-Sevilla, Norma
    FRONTIERS IN MEDICINE, 2023, 10
  • [23] Treatment of COVID-19 Patients with mild or moderate Disease
    Lichert, Frank
    PNEUMOLOGIE, 2021, 75 (03): : 174 - 174
  • [24] Effects of L-carnitine supplementation in patients with mild-to-moderate COVID-19 disease: a pilot study
    Seyed Saman Talebi
    Mehran Ghasemi
    Maryam Etminani-Esfahani
    Younes Mohammadi
    Rasool Haddadi
    Pharmacological Reports, 2022, 74 : 1296 - 1305
  • [25] Effects of L-carnitine supplementation in patients with mild-to-moderate COVID-19 disease: a pilot study
    Talebi, Seyed Saman
    Ghasemi, Mehran
    Etminani-Esfahani, Maryam
    Mohammadi, Younes
    Haddadi, Rasool
    PHARMACOLOGICAL REPORTS, 2022, 74 (06) : 1296 - 1305
  • [26] A randomized phase 2 study on demeclocycline in patients with mild-to-moderate COVID-19
    Kota Iwahori
    Takuro Nii
    Norihiko Yamaguchi
    Takahiro Kawasaki
    Satomi Okamura
    Kazuki Hashimoto
    Takanori Matsuki
    Kazuyuki Tsujino
    Keisuke Miki
    Akio Osa
    Sho Goya
    Kinya Abe
    Masahide Mori
    Yoshito Takeda
    Tomomi Yamada
    Hiroshi Kida
    Atsushi Kumanogoh
    Scientific Reports, 13
  • [27] Oral symptoms potentially associated with mild-to-moderate COVID-19 in tobacco users
    Alkharobi, Hanaa E.
    TOBACCO INDUCED DISEASES, 2024, 22
  • [28] Clinical and subclinical acute kidney injury in children with mild-to-moderate COVID-19
    Seha Saygili
    Nur Canpolat
    Rumeysa Yasemin Cicek
    Ayse Agbas
    Esra Karabag Yilmaz
    Ayse Ayzit Kilinc Sakalli
    Deniz Aygun
    Gülsen Akkoc
    Kaan Can Demirbas
    Dildar Konukoglu
    Haluk Cokugras
    Salim Caliskan
    Lale Sever
    Pediatric Research, 2023, 93 : 654 - 660
  • [29] Cognitive Impairment in Non-critical, Mild-to-Moderate COVID-19 Survivors
    Henneghan, Ashley M.
    Lewis, Kimberly A.
    Gill, Eliana
    Kesler, Shelli R.
    FRONTIERS IN PSYCHOLOGY, 2022, 13
  • [30] Monoclonal Antibody and Antiviral Therapy for Mild-to-Moderate COVID-19 in Pediatric Patients
    Vora, Surabhi B. B.
    Englund, Janet A. A.
    Trehan, Indi
    Waghmare, Alpana
    Kong, Ada
    Adler, Amanda
    Zerr, Danielle M. M.
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2023, 42 (01) : 32 - 34